EyePoint Pharmaceuticals, Inc. (EYPT) has reported an initial statement of beneficial ownership of securities filed by director and 10% owner, Fred Hassan. The SEC Form 3, filed on September 3, 2024, indicates that Hassan does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Ron Honig on September 5, 2024, is a routine disclosure required by the United States Securities and Exchange Commission for individuals in Hassan's position.

EyePoint Pharmaceuticals, Inc. (EYPT) has reported an initial statement of beneficial ownership of securities filed by director and 10% owner, Fred Hassan. The SEC Form 3, filed on September 3, 2024, indicates that Hassan does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Ron Honig on September 5, 2024, is a routine disclosure required by the United States Securities and Exchange Commission for individuals in Hassan's position.